Clusterin 詳細
Molecule Name
Clusterin
分子の別称
CLU,Clusterin,AAG4,APOJ,CLI,KUB1,SGP-2,SP-40,TRPM2
Drug Development Progress
治験薬の数1
市販薬剤の数0
研究＆開発段階Phase 2 Clinical
ターゲットの別称
Epididymis Secretory Sperm Binding Protein，CLI，Apolipoprotein J，ApoJbeta，Complement cytolysis inhibitor a chain，Testosterone-repressed prostate message 2，Complement cytolysis inhibitor b chain，ApoJalpha，AAG4，Complement cytolysis inhibitor，NA1/NA2，APOJ，CLU，Clusterin，Complement-Associated Protein SP-40，40，Complement Lysis Inhibitor，Sulfated Glycoprotein 2，Ku70-Binding Protein 1，TRPM-2，KUB1，Clusterin (Complement Lysis Inhibitor， SP-40，40， Sulfated Glycoprotein 2， Testosterone-Repressed Prostate Message 2， Apolipoprotein J)，Aging-Associated Gene 4 Protein，Aging-Associated Protein 4，APO-J，SGP-2，SP-40，CLU1，CLU2，SGP2，TRPM2
バックグランド
Clusterin (CLU/ApoJ) is a sticky, CHO-derived glycoprotein secreted as a ~75–80 kDa disulfide-linked heterodimer. Due to hydrophobic/glycan-mediated interactions, it often co-purifies with mAbs and persists through Protein A, posing risks to product stability. As a high-priority HCP, residual CLU requires targeted monitoring via orthogonal methods (LC-MS/MS or specific ELISA) alongside total HCP assays.
Clusterin 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Sotevtamab | AB-sCLU mAB; 16B5; AB-16B5 | Phase 2 Clinical | National Research Council Biotechnology Research Institute | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasm Metastasis; Solid tumours | 詳細 |